Hypoesthesia

Texas Original Compassionate Cultivation Partners with Cannabis Infusion Leader Vertosa

Retrieved on: 
Wednesday, August 25, 2021
General Health, Health, Retail, Tobacco, Pharmaceutical, Expanded access, Emulsion, Instagram, Anxiety, Science, Physician, Neuropathic pain, Nausea, Hypoesthesia, Chronic pain, Patient, Solution, CEO, LinkedIn, Taste, Spasm, Medicine, Drug, Pharmaceutical industry, Texas Original Compassionate Cultivation, Vertosa, TEXAS ORIGINAL COMPASSIONATE CULTIVATION, VERTOSA

Texas Original Compassionate Cultivation (TOCC), Texas leading medical cannabis provider, today announced it has partnered with Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.

Key Points: 
  • Texas Original Compassionate Cultivation (TOCC), Texas leading medical cannabis provider, today announced it has partnered with Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.
  • TOCCs proven medical cannabis products will be the first and only in Texas to feature Vertosas solutions.
  • As the medical cannabis leader in Texas, were always looking for ways to create and improve products on behalf of our patients, said Morris Denton, CEO of TOCC.
  • Texas Original Compassionate Cultivation (TOCC) is the leading licensed medical marijuana producer in Texas, working alongside physicians to provide the highest quality cannabis medicine to patients and families seeking relief across the state.

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Retrieved on: 
Monday, August 23, 2021
Family, Health, Consumer, Women, Baby, Maternity, General Health, Pharmaceutical, Center, Centers for Medicare & Medicaid Services, Atrial fibrillation, Blood, J-CODE, Cancer, Forehead, Population, Skin, Population Council, Mouth, CMS, Weakness, Diabetes, HCPCS Level 2, Toxic shock syndrome, TSS, Medicare, Liver, Death, Chin, Heart, Thrombus, Vaginal bleeding, Hypoesthesia, Infection, Healthcare Common Procedure Coding System, NASDAQ, Risk, Patient, Headache, Depression, Public health, Angioedema, Liver disease, FDA, HCPCS, Smoke, Stroke, Progesterone, Breast cancer, Woman, Cholesterol, Triglyceride, Center for Medicare and Medicaid Innovation, Smoking, Medicine, Health insurance, Birth control, Medical imaging, Pharmaceutical industry, ANNOVERA, TherapeuticsMD, ANNOVERA, THERAPEUTICSMD

This new J Code will allow dispensing Public Health facilities the opportunity to gain reimbursement for ANNOVERA, including the approximately 4,900 Title X Family Planning clinics.

Key Points: 
  • This new J Code will allow dispensing Public Health facilities the opportunity to gain reimbursement for ANNOVERA, including the approximately 4,900 Title X Family Planning clinics.
  • Public Health claims submission and payment are standardized with a J Code, facilitating and streamlining billing and reimbursement.
  • Public Health insured patients represent a growing segment of the ANNOVERA user base.
  • Having a permanent J Code will simplify Public Health billing and payment, further enhancing patient access to ANNOVERA in a growing segment of our user base.

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

Retrieved on: 
Wednesday, May 12, 2021
Symptoms and signs, Branches of biology, Medicine, XC2, Hallucinations, Paresthesia, Tetany, Forward-looking statement, Hypoesthesia, Headache, Pharma

In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache.

Key Points: 
  • In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache.
  • Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements.
  • Securities and Exchange Commission\xc2\xa0(SEC)\xc2\xa0on\xc2\xa0March 10, 2021 and Ascendis\xe2\x80\x99 other future reports filed with, or submitted to, the SEC.
  • Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.\nAscendis,\xc2\xa0Ascendis Pharma, the\xc2\xa0Ascendis Pharma\xc2\xa0logo, the company logo and TransCon are trademarks owned by the\xc2\xa0Ascendis Pharma Group.

Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organ systems, Medicine, Clinical medicine, Pain, Brentuximab vedotin, Takeda Pharmaceutical Company, Peripheral neuropathy, Neurological disorders, Hypoesthesia, Neuropathic pain, Dysesthesia, Paresthesia, ICLUSIG® (ponatinib) tablets, NINLARO™

Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.

Key Points: 
  • Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
  • Available data indicate that MMAE clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations.
  • Patients who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk of neutropenia.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses

Retrieved on: 
Thursday, May 16, 2019
Health, Biotechnology, Clinical trials, Genetics, Oncology, Pharmaceutical, Research, Science, Medicine, Clinical medicine, Organ systems, Takeda Pharmaceutical Company, Neurological disorders, Brentuximab vedotin, Hypoesthesia, Peripheral neuropathy, Paresthesia, Dysesthesia, Hyperesthesia

Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.

Key Points: 
  • Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
  • Patients who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk of neutropenia.
  • There are no data from the use of ADCETRIS in pregnant women, although studies in animals have shown reproductive toxicity.
  • Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases.